Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 97

1.

A Novel Marine Natural Product Derived Pyrroloiminoquinone with Potent Activity against Skin Cancer Cells.

Cowan J, Shadab M, Nadkarni DH, Kc K, Velu SE, Yusuf N.

Mar Drugs. 2019 Jul 27;17(8). pii: E443. doi: 10.3390/md17080443.

2.

Clustering of Janus particles in an optical potential driven by hydrodynamic fluxes.

Mousavi SM, Kasianiuk I, Kasyanyuk D, Velu SKP, Callegari A, Biancofiore L, Volpe G.

Soft Matter. 2019 Jul 17;15(28):5748-5759. doi: 10.1039/c8sm02282h.

PMID:
31281912
3.

MDM2-NFAT1 dual inhibitor, MA242: Effective against hepatocellular carcinoma, independent of p53.

Wang W, Cheng JW, Qin JJ, Hu B, Li X, Nijampatnam B, Velu SE, Fan J, Yang XR, Zhang R.

Cancer Lett. 2019 Sep 10;459:156-167. doi: 10.1016/j.canlet.2019.114429. Epub 2019 Jun 7.

PMID:
31181320
4.

Factors influencing the choice of low-vision devices for visual rehabilitation in Stargardt disease.

Das K, Gopalakrishnan S, Dalan D, Velu S, Ratra V, Ratra D.

Clin Exp Optom. 2019 Jul;102(4):426-433. doi: 10.1111/cxo.12867. Epub 2018 Dec 24.

PMID:
30582217
5.

Active matter alters the growth dynamics of coffee rings.

Andac T, Weigmann P, Velu SKP, Pinçe E, Volpe G, Volpe G, Callegari A.

Soft Matter. 2019 Feb 13;15(7):1488-1496. doi: 10.1039/c8sm01350k.

PMID:
30570633
6.

Discovery and Characterization of Dual Inhibitors of MDM2 and NFAT1 for Pancreatic Cancer Therapy.

Wang W, Qin JJ, Voruganti S, Nijampatnam B, Velu SE, Ruan KH, Hu M, Zhou J, Zhang R.

Cancer Res. 2018 Oct 1;78(19):5656-5667. doi: 10.1158/0008-5472.CAN-17-3939. Epub 2018 Sep 14.

7.

Biochemical and Epigenetic Insights into L-2-Hydroxyglutarate, a Potential Therapeutic Target in Renal Cancer.

Shelar S, Shim EH, Brinkley GJ, Kundu A, Carobbio F, Poston T, Tan J, Parekh V, Benson D, Crossman DK, Buckhaults PJ, Rakheja D, Kirkman R, Sato Y, Ogawa S, Dutta S, Velu SE, Emberley E, Pan A, Chen J, Huang T, Absher D, Becker A, Kunick C, Sudarshan S.

Clin Cancer Res. 2018 Dec 15;24(24):6433-6446. doi: 10.1158/1078-0432.CCR-18-1727. Epub 2018 Aug 14.

8.

Inhibition of Streptococcus mutans Biofilms by the Natural Stilbene Piceatannol Through the Inhibition of Glucosyltransferases.

Nijampatnam B, Zhang H, Cai X, Michalek SM, Wu H, Velu SE.

ACS Omega. 2018 Jul 31;3(7):8378-8385. doi: 10.1021/acsomega.8b00367. Epub 2018 Jul 30.

9.

An Expedient Synthesis of Murrayaquinone A via a Novel Oxidative Free Radical Reaction.

McDonald JW, Miller JE, Kim M, Velu SE.

Tetrahedron Lett. 2018 Feb 7;59(6):550-553. doi: 10.1016/j.tetlet.2018.01.007. Epub 2018 Jan 4.

10.

Discovery and evaluation of nNav1.5 sodium channel blockers with potent cell invasion inhibitory activity in breast cancer cells.

Dutta S, Lopez Charcas O, Tanner S, Gradek F, Driffort V, Roger S, Selander K, Velu SE, Brouillette W.

Bioorg Med Chem. 2018 May 15;26(9):2428-2436. doi: 10.1016/j.bmc.2018.04.003. Epub 2018 Apr 3.

11.

Structure-Based Discovery of Small Molecule Inhibitors of Cariogenic Virulence.

Zhang Q, Nijampatnam B, Hua Z, Nguyen T, Zou J, Cai X, Michalek SM, Velu SE, Wu H.

Sci Rep. 2017 Jul 20;7(1):5974. doi: 10.1038/s41598-017-06168-1.

12.

Highly efficient delivery of potent anticancer iminoquinone derivative by multilayer hydrogel cubes.

Xue B, Wang W, Qin JJ, Nijampatnam B, Murugesan S, Kozlovskaya V, Zhang R, Velu SE, Kharlampieva E.

Acta Biomater. 2017 Aug;58:386-398. doi: 10.1016/j.actbio.2017.06.004. Epub 2017 Jun 3.

13.

Toll-like receptor 9 expression is associated with breast cancer sensitivity to the growth inhibitory effects of bisphosphonates in vitro and in vivo.

Sandholm J, Lehtimäki J, Ishizu T, Velu SE, Clark J, Härkönen P, Jukkola-Vuorinen A, Schrey A, Harris KW, Tuomela JM, Selander KS.

Oncotarget. 2016 Dec 27;7(52):87373-87389. doi: 10.18632/oncotarget.13570.

14.

Hydroxychalcone inhibitors of Streptococcus mutans glucosyl transferases and biofilms as potential anticaries agents.

Nijampatnam B, Casals L, Zheng R, Wu H, Velu SE.

Bioorg Med Chem Lett. 2016 Aug 1;26(15):3508-13. doi: 10.1016/j.bmcl.2016.06.033. Epub 2016 Jun 14.

15.

Disorder-mediated crowd control in an active matter system.

Pinçe E, Velu SK, Callegari A, Elahi P, Gigan S, Volpe G, Volpe G.

Nat Commun. 2016 Mar 9;7:10907. doi: 10.1038/ncomms10907.

16.

Mitochondrial thiol modification by a targeted electrophile inhibits metabolism in breast adenocarcinoma cells by inhibiting enzyme activity and protein levels.

Smith MR, Vayalil PK, Zhou F, Benavides GA, Beggs RR, Golzarian H, Nijampatnam B, Oliver PG, Smith RA, Murphy MP, Velu SE, Landar A.

Redox Biol. 2016 Aug;8:136-48. doi: 10.1016/j.redox.2016.01.002. Epub 2016 Jan 8.

17.

Cyanobacterial Metabolite Calothrixins: Recent Advances in Synthesis and Biological Evaluation.

Xu S, Nijampatnam B, Dutta S, Velu SE.

Mar Drugs. 2016 Jan 12;14(1):17. doi: 10.3390/md14010017. Review.

18.

Channel Gating Regulation by the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) First Cytosolic Loop.

Ehrhardt A, Chung WJ, Pyle LC, Wang W, Nowotarski K, Mulvihill CM, Ramjeesingh M, Hong J, Velu SE, Lewis HA, Atwell S, Aller S, Bear CE, Lukacs GL, Kirk KL, Sorscher EJ.

J Biol Chem. 2016 Jan 22;291(4):1854-65. doi: 10.1074/jbc.M115.704809. Epub 2015 Dec 1.

19.

Mangrove rare actinobacteria: taxonomy, natural compound, and discovery of bioactivity.

Azman AS, Othman I, Velu SS, Chan KG, Lee LH.

Front Microbiol. 2015 Aug 20;6:856. doi: 10.3389/fmicb.2015.00856. eCollection 2015. Review.

20.

Recent advances in isolation, synthesis, and evaluation of bioactivities of bispyrroloquinone alkaloids of marine origin.

Nijampatnam B, Dutta S, Velu SE.

Chin J Nat Med. 2015 Aug;13(8):561-77. doi: 10.1016/S1875-5364(15)30052-2. Review.

21.

Development and validation of an HPLC-MS/MS analytical method for quantitative analysis of TCBA-TPQ, a novel anticancer makaluvamine analog, and application in a pharmacokinetic study in rats.

Yu JX, Voruganti S, Li DD, Qin JJ, Nag S, Xu S, Velu SE, Wang W, Zhang R.

Chin J Nat Med. 2015 Jul;13(7):554-60. doi: 10.1016/S1875-5364(15)30051-0.

22.

New small-molecule inhibitors of dihydrofolate reductase inhibit Streptococcus mutans.

Zhang Q, Nguyen T, McMichael M, Velu SE, Zou J, Zhou X, Wu H.

Int J Antimicrob Agents. 2015 Aug;46(2):174-82. doi: 10.1016/j.ijantimicag.2015.03.015. Epub 2015 May 8.

23.

Honokiol inhibits the growth of head and neck squamous cell carcinoma by targeting epidermal growth factor receptor.

Singh T, Gupta NA, Xu S, Prasad R, Velu SE, Katiyar SK.

Oncotarget. 2015 Aug 28;6(25):21268-82.

24.

A novel class of mitochondria-targeted soft electrophiles modifies mitochondrial proteins and inhibits mitochondrial metabolism in breast cancer cells through redox mechanisms.

Vayalil PK, Oh JY, Zhou F, Diers AR, Smith MR, Golzarian H, Oliver PG, Smith RA, Murphy MP, Velu SE, Landar A.

PLoS One. 2015 Mar 18;10(3):e0120460. doi: 10.1371/journal.pone.0120460. eCollection 2015.

25.

Total Synthesis of Calothrixins A and B via Oxidative Radical Reaction of Cyclohexenone with Aminophenanthridinedione.

Xu S, Nguyen T, Pomilio I, Vitale MC, Velu SE.

Tetrahedron. 2014 Sep 2;70(35):5928-5933.

26.

L-2-Hydroxyglutarate: an epigenetic modifier and putative oncometabolite in renal cancer.

Shim EH, Livi CB, Rakheja D, Tan J, Benson D, Parekh V, Kho EY, Ghosh AP, Kirkman R, Velu S, Dutta S, Chenna B, Rea SL, Mishur RJ, Li Q, Johnson-Pais TL, Guo L, Bae S, Wei S, Block K, Sudarshan S.

Cancer Discov. 2014 Nov;4(11):1290-8. doi: 10.1158/2159-8290.CD-13-0696. Epub 2014 Sep 2.

27.

Colloidal assemblies of oriented maghemite nanocrystals and their NMR relaxometric properties.

Kostopoulou A, Velu SK, Thangavel K, Orsini F, Brintakis K, Psycharakis S, Ranella A, Bordonali L, Lappas A, Lascialfari A.

Dalton Trans. 2014 Jun 14;43(22):8395-404. doi: 10.1039/c4dt00024b.

PMID:
24740193
28.

Quantification of strain and charge co-mediated magnetoelectric coupling on ultra-thin Permalloy/PMN-PT interface.

Nan T, Zhou Z, Liu M, Yang X, Gao Y, Assaf BA, Lin H, Velu S, Wang X, Luo H, Chen J, Akhtar S, Hu E, Rajiv R, Krishnan K, Sreedhar S, Heiman D, Howe BM, Brown GJ, Sun NX.

Sci Rep. 2014 Jan 14;4:3688. doi: 10.1038/srep03688.

29.

Antibacterial and Antibiofilm Activities of Makaluvamine Analogs.

Nijampatnam B, Nadkarni DH, Wu H, Velu SE.

Microorganisms. 2014;2(3):128-39. doi: 10.3390/microorganisms2030128.

30.

Total synthesis of zyzzyanones A-D.

Nadkarni DH, Murugesan S, Velu SE.

Tetrahedron. 2013 May 20;69(20):4105-4113.

31.

Identification of the ZAK-MKK4-JNK-TGFβ signaling pathway as a molecular target for novel synthetic iminoquinone anticancer compound BA-TPQ.

Chen D, Wang W, Qin JJ, Wang MH, Murugesan S, Nadkarni DH, Velu SE, Wang H, Zhang R.

Curr Cancer Drug Targets. 2013 Jul;13(6):651-60.

32.

Attenuation of nonsense-mediated mRNA decay enhances in vivo nonsense suppression.

Keeling KM, Wang D, Dai Y, Murugesan S, Chenna B, Clark J, Belakhov V, Kandasamy J, Velu SE, Baasov T, Bedwell DM.

PLoS One. 2013 Apr 10;8(4):e60478. doi: 10.1371/journal.pone.0060478. Print 2013.

33.

Characterization of strain recovery and "self-healing" in a self-assembled metallo-gel.

Terech P, Yan M, Maréchal M, Royal G, Galvez J, Velu SK.

Phys Chem Chem Phys. 2013 May 21;15(19):7338-44. doi: 10.1039/c3cp50671a.

PMID:
23575452
34.

Metallosupramolecular thin films using a tritopic cyclam-based ligand.

Yan M, Velu SK, Royal G, Terech P.

J Colloid Interface Sci. 2013 Jun 1;399:6-12. doi: 10.1016/j.jcis.2013.02.034. Epub 2013 Mar 7.

PMID:
23540829
35.

Regio- and stereocontrolled synthesis of oligostilbenoids: theoretical highlights at the supramolecular level.

Velu SS, Di Meo F, Trouillas P, Sancho-Garcia JC, Weber JF.

J Nat Prod. 2013 Apr 26;76(4):538-46. doi: 10.1021/np300705p. Epub 2013 Feb 26.

PMID:
23441649
36.

Synthesis of Pyrroloquinones via a CAN Mediated Oxidative Free Radical Reaction of 1,3-Dicarbonyl Compounds with Aminoquinones.

Nguyen T, Nadkarni D, Dutta S, Xu S, Kim S, Murugesan S, Velu S.

J Chem. 2013;2013. pii: 262580.

37.

Mini-review: bmx kinase inhibitors for cancer therapy.

Jarboe JS, Dutta S, Velu SE, Willey CD.

Recent Pat Anticancer Drug Discov. 2013 Sep;8(3):228-38. Review.

PMID:
23198769
38.

Pharmaceutical care for asthma patients: A Developing Country's Experience.

Shanmugam S, Varughese J, Nair MA, Balasubramanian R, Velu S, Bhojan C, Devarajan V, Sabzghabaee AM.

J Res Pharm Pract. 2012 Oct;1(2):66-71. doi: 10.4103/2279-042X.108373.

39.

Preclinical evaluation of anticancer efficacy and pharmacological properties of FBA-TPQ, a novel synthetic makaluvamine analog.

Zhang X, Xu H, Zhang X, Voruganti S, Murugesan S, Nadkarni DH, Velu SE, Wang MH, Wang W, Zhang R.

Mar Drugs. 2012 May;10(5):1138-55. doi: 10.3390/md10051138. Epub 2012 May 23.

40.

Renal function and aspirin resistance in patients with coronary artery disease.

Blann AD, Kuzniatsova N, Velu S, Lip GY.

Thromb Res. 2012 Sep;130(3):e103-6. doi: 10.1016/j.thromres.2012.06.026. Epub 2012 Jul 17.

PMID:
22809843
41.

Understanding health information needs and gaps in the health care system in Uttar Pradesh, India.

Kapadia-Kundu N, Sullivan TM, Safi B, Trivedi G, Velu S.

J Health Commun. 2012;17 Suppl 2:30-45. doi: 10.1080/10810730.2012.666625.

PMID:
22724670
42.

3,5-dibenzyloxy-4'-hydroxystilbene induces early caspase-9 activation during apoptosis in human K562 chronic myelogenous leukemia cells.

Roslie H, Chan KM, Rajab NF, Velu SS, Kadir SA, Bunyamin I, Weber JF, Thomas NF, Majeed AB, Myatt G, Inayat-Hussain SH.

J Toxicol Sci. 2012 Feb;37(1):13-21.

43.

Experimental therapy of ovarian cancer with synthetic makaluvamine analog: in vitro and in vivo anticancer activity and molecular mechanisms of action.

Chen T, Xu Y, Guo H, Liu Y, Hu P, Yang X, Li X, Ge S, Velu SE, Nadkarni DH, Wang W, Zhang R, Wang H.

PLoS One. 2011;6(6):e20729. doi: 10.1371/journal.pone.0020729. Epub 2011 Jun 6.

44.

Elevated levels of NO are localized to distal airways in asthma.

Anderson JT, Zeng M, Li Q, Stapley R, Moore DR 2nd, Chenna B, Fineberg N, Zmijewski J, Eltoum IE, Siegal GP, Gaggar A, Barnes S, Velu SE, Thannickal VJ, Abraham E, Patel RP, Lancaster JR Jr, Chaplin DD, Dransfield MT, Deshane JS.

Free Radic Biol Med. 2011 Jun 1;50(11):1679-88. doi: 10.1016/j.freeradbiomed.2011.03.015. Epub 2011 Mar 16. Erratum in: Free Radic Biol Med. 2013 May;58:45.

45.

What is the role of the cardiologist in future management of stroke prevention in atrial fibrillation?

Velu S, Lip GY.

Adv Ther. 2011 Jan;28(1):1-12. doi: 10.1007/s12325-010-0091-9. Epub 2010 Dec 6. Review.

PMID:
21153001
46.

Recent progress in antithrombotic therapy for atrial fibrillation.

Velu S, Lip GY.

J Atheroscler Thromb. 2011;18(4):257-73. Epub 2010 Nov 13. Review.

47.

Development and validation of an HPLC method for quantitation of BA-TPQ, a novel iminoquinone anticancer agent, and an initial pharmacokinetic study in mice.

Li H, Ezell SJ, Zhang X, Wang W, Xu H, Rayburn ER, Zhang X, Gurpinar E, Yang X, Sommers CI, Velu SE, Zhang R.

Biomed Chromatogr. 2011 May;25(5):628-634. doi: 10.1002/bmc.1498. Epub 2010 Sep 15.

48.

Preclinical pharmacology of BA-TPQ, a novel synthetic iminoquinone anticancer agent.

Ezell SJ, Li H, Xu H, Zhang X, Gurpinar E, Zhang X, Rayburn ER, Sommers CI, Yang X, Velu SE, Wang W, Zhang R.

Mar Drugs. 2010 Jul 13;8(7):2129-41. doi: 10.3390/md8072129.

49.

Synthesis and structure activity relationship studies of novel Staphylococcus aureus Sortase A inhibitors.

Chenna BC, King JR, Shinkre BA, Glover AL, Lucius AL, Velu SE.

Eur J Med Chem. 2010 Sep;45(9):3752-61. doi: 10.1016/j.ejmech.2010.05.024. Epub 2010 May 20.

50.

Synthesis and characterization of potent inhibitors of Trypanosoma cruzi dihydrofolate reductase.

Schormann N, Velu SE, Murugesan S, Senkovich O, Walker K, Chenna BC, Shinkre B, Desai A, Chattopadhyay D.

Bioorg Med Chem. 2010 Jun 1;18(11):4056-66. doi: 10.1016/j.bmc.2010.04.020. Epub 2010 Apr 9.

PMID:
20452776

Supplemental Content

Support Center